Evidence map›Paper›PMID 41908822›Full record

ArticleFrontiers in pharmacology2026

Applicability of academic real-world data research in the case studies of the HTx project to practical health technology assessment work.

Carl Björvang, Johan Pontén, Anders Viberg, Andrea Manca, Georgia Salanti, Pekka Siirtola, Gema García-Sáez, Saskia Knies, Diana Delnoij, Dalia Dawoud and 4 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Carl BjörvangDental and Pharmaceutical Benefits Agency, Stockholm, Sweden.
Johan PonténDental and Pharmaceutical Benefits Agency, Stockholm, Sweden.
Anders VibergDental and Pharmaceutical Benefits Agency, Stockholm, Sweden.
Andrea MancaCentre for Health Economics, University of York, York, United Kingdom.
Georgia SalantiInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Pekka SiirtolaBiomimetics and Intelligent Systems Group, University of Oulu, Oulu, Finland.
Gema García-SáezBioengineering and Telemedicine Group, Centrode Tecnología Biomédica, ETSI de Telecomunicación, Universidad Politécnica de Madrid, Madrid, Spain.
Saskia KniesNational Healthcare Institute, Diemen, Netherlands.
Diana DelnoijNational Healthcare Institute, Diemen, Netherlands.
Dalia DawoudFaculty of Pharmacy, University of Cairo, Cairo, Egypt.
Jamie ElvidgeScience Policy and Research Programme, National Institute for Health and Care Excellence (NICE), London, United Kingdom.
Lifang LiuDepartment of Statistics, European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
Bertalan NémethSyreon Research Institute, Budapest, Hungary.
Zoltán KalóSyreon Research Institute, Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Next-Generation HTA (HTx) is a recently finalised EU project which aimed to connect academic HTA researchers with HTA practitioners. Methods: This paper studies the applicability of the academic RWD research conducted through four case studies within the HTx project to practical HTA work. As a first step HTA Agency representatives of the HTx consortium sent a survey out to each case study leader, enquiring about the usefulness of their RWD research methods for HTA agencies in various situations, and barriers to their utilisation. The second step was to conduct follow-up interviews with the case study leaders, to further understand the new RWD research methods and their applicability to HTA practices. Results: The results show a great variety in when and how the methods could be used for practical HTA evaluations. Generally, there was a high potential for the RWD research methods to be used to estimate treatment effects and cost-effectiveness, while they were less adapted for estimating natural disease progression and identifying relevant comparators. However, there were significant barriers to the use of these methods for practical HTA evaluations, even in the aspects of evaluations the methods were designed to handle. These barriers ranged from the availability of RWD and need for partial reliance on RCT data, to required expertise in areas such as data evaluation, statistics and medical knowledge. Discussion: The case studies show that RWD can be used for a range of HTA aspects and in various situations. However, no RWD research method is a silver bullet that is applicable for all aspects in all situations. As such, they can make significant contributions to the work of HTA agencies, but as part of a wider tool set.

Indexed as

cost-effectivenesshealth technology assessmentHTxrandomized controlled trial datareal-world datatransferabilitytreatment effect

Identifiers

PMID41908822
PMCPMC13021581

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.